Prognostic Impact of Statins in Heart Failure with Preserved Ejection Fraction.

Autor: Ortega-Hernández S; Internal Medicine Department, Hospital Universitario de Gran Canaria Dr. Negrín, 35010 Las Palmas de Gran Canaria, Las Palmas, Spain., González-Sosa S; Internal Medicine Department, Hospital Universitario de Gran Canaria Dr. Negrín, 35010 Las Palmas de Gran Canaria, Las Palmas, Spain.; Health Sciences Faculty, Universidad de Las Palmas de Gran Canaria, 35016 Las Palmas, Spain., Conde-Martel A; Internal Medicine Department, Hospital Universitario de Gran Canaria Dr. Negrín, 35010 Las Palmas de Gran Canaria, Las Palmas, Spain.; Health Sciences Faculty, Universidad de Las Palmas de Gran Canaria, 35016 Las Palmas, Spain., Trullàs JC; Internal Medicine Department, Hospital d'Olot i Comarcal de la Garrotxa, 17800 Girona, Spain.; Tissue Repair and Regeneration Laboratory (TR2Lab), Institut de Recerca i Innovació en Ciències de la Vida i de la Salut a la Catalunya Central (IrisCC), Faculty of Medicine, University of Vic-Central University of Catalonia (UVic-UCC), Ctra. de Roda, 70, 08500 Vic, Barcelona, Spain., Llàcer P; Internal Medicine Department, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Universidad de Alcalá, 28801 Madrid, Spain., Pérez-Silvestre J; Internal Medicine Department, Consorcio Hospital General Universitario de Valencia, 46014 Valencia, Spain., Arévalo-Lorido JC; FundeSalud, 06800 Mérida, Badajoz, Spain., Casado J; Internal Medicine Department, Hospital Universitario de Getafe, 28905 Madrid, Spain.; Facultad de Ciencias Biomédicas y de la Salud, Universidad Europea de Madrid, 28670 Madrid, Spain., Formiga F; Internal Medicine Department, Hospital Universitario Bellvitge, 08907 L'Hospitalet de Llobregat, Barcelona, Spain., Manzano L; Internal Medicine Department, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Universidad de Alcalá, 28801 Madrid, Spain., Lorenzo-Villalba N; Service de Médecine Interne, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France., Montero-Pérez-Barquero M; Internal Medicine Department, Hospital Universitario Reina Sofía, 14004 Córdoba, Spain.
Jazyk: angličtina
Zdroj: Journal of clinical medicine [J Clin Med] 2024 Sep 30; Vol. 13 (19). Date of Electronic Publication: 2024 Sep 30.
DOI: 10.3390/jcm13195844
Abstrakt: Background: Heart failure (HF) with preserved ejection fraction (pEF) has lacked effective treatments for reducing mortality. However, previous studies have found an association between statin use and decreased mortality in patients with HFpEF. The aim of this study was to analyse whether statin therapy is associated with a reduction in mortality in these patients and whether the effect differs according to the presence or absence of ischaemic heart disease (IHD). Methods: We analysed data from the National Registry of Heart Failure, a prospective study that included patients admitted for HF in Internal Medicine units nationwide. Patients with HFpEF were classified according to the use of statins, and the differences between the two groups were analysed. A multivariable analysis was performed using Cox regression to assess factors independently related to mortality. Results: A total of 2788 patients with HFpEF were included; 63% of them were women with a mean age of 80.1 (±7.8) years. The statin-treated group (40.2%) was younger, with better functional status, and had a more common diagnosis of vascular disease and lower frequency of atrial fibrillation. The most frequent aetiology of HF in both groups was the hypertensive one. Nevertheless, ischaemic HF was more common in those who received statins (24.8% vs. 9.6%; p < 0.001). Multivariable analysis showed lower mortality at the 1-year follow-up in statin-treated patients (OR: 0.74; 95%CI: 0.61-0.89; p = 0.002). This association was observed in patients without IHD ( p < 0.001) but not in those with IHD ( p = 0.11). Conclusions: Statins are associated with a decrease in total mortality in patients with HFpEF. This benefit occurs mainly in those without IHD.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje